Filtered By:
Specialty: Internal Medicine
Condition: Patent Foramen Ovale

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 47 results found since Jan 2013.

Adding patent foramen ovale closure to antiplatelet drugs reduced ischemic stroke after cryptogenic stroke.
PMID: 29335718 [PubMed - in process]
Source: Annals of Internal Medicine - January 16, 2018 Category: Internal Medicine Authors: Alberts MJ Tags: Ann Intern Med Source Type: research

Device Closure Versus Medical Therapy Alone for Patent Foramen Ovale in Patients With Cryptogenic Stroke: A Systematic Review and Meta-analysis.
Conclusion: In patients with PFO and cryptogenic stroke, transcatheter device closure decreases risk for recurrent stroke compared with medical therapy alone. Because recurrent stroke rates are low even with medical therapy alone and PFO closure might affect AF risk, shared decision making is crucial for this treatment. Primary Funding Source: None. PMID: 29310136 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - January 9, 2018 Category: Internal Medicine Authors: Shah R, Nayyar M, Jovin IS, Rashid A, Bondy BR, Fan TM, Flaherty MP, Rao SV Tags: Ann Intern Med Source Type: research

Percutaneous Closure Versus Medical Treatment in Stroke Patients With Patent Foramen Ovale: A Systematic Review and Meta-analysis.
Conclusion: Compared with medical treatment, PFO closure prevents recurrent stroke and TIA but increases the incidence of AF or AFL in PFO carriers with cryptogenic stroke. Primary Funding Source: Italian Ministry of Education, University and Research (MIUR). (PROSPERO: CRD42017074686). PMID: 29310133 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - January 9, 2018 Category: Internal Medicine Authors: De Rosa S, Sievert H, Sabatino J, Polimeni A, Sorrentino S, Indolfi C Tags: Ann Intern Med Source Type: research

Patent Foramen Ovale after Cryptogenic Stroke — Assessing the Evidence for Closure
New England Journal of Medicine,Volume 377, Issue 11, Page 1006-1009, September 2017.
Source: New England Journal of Medicine - September 13, 2017 Category: Internal Medicine Authors: Andrew Farb Nicole G. Ibrahim Bram D. Zuckerman Source Type: research

Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke
New England Journal of Medicine,Volume 377, Issue 11, Page 1011-1021, September 2017.
Source: New England Journal of Medicine - September 13, 2017 Category: Internal Medicine Authors: Jean-Louis Mas Genevi ève Derumeaux Beno ît Guillon Evelyne Massardier Hassan Hosseini Laura Mechtouff Caroline Arquizan Yannick B éjot Fabrice Vuillier Olivier Detante C éline Guidoux Sandrine Canaple Claudia Vaduva Nelly Dequatre-Ponchelle Igor Sibo Source Type: research

Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
New England Journal of Medicine,Volume 377, Issue 11, Page 1022-1032, September 2017.
Source: New England Journal of Medicine - September 13, 2017 Category: Internal Medicine Authors: Jeffrey L. Saver John D. Carroll David E. Thaler Richard W. Smalling Lee A. MacDonald David S. Marks David L. Tirschwell Source Type: research

Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
New England Journal of Medicine,Volume 377, Issue 11, Page 1033-1042, September 2017.
Source: New England Journal of Medicine - September 13, 2017 Category: Internal Medicine Authors: Lars S øndergaard Scott E. Kasner John F. Rhodes Grethe Andersen Helle K. Iversen Jens E. Nielsen-Kudsk Magnus Settergren Christina Sj östrand Risto O. Roine David Hildick-Smith J. David Spence Lars Thomassen Source Type: research

Patent foramen ovale closure to prevent secondary neurologic events.
Abstract In October of 2016 the United States Food and Drug Administration approved the Amplatzer Patent Foramen Ovale (PFO) occluder device for use in patients with cryptogenic stroke, to reduce the risk of recurrent stroke. This event followed 15years of off-label use of atrial septal occluder devices, 3 randomized trials, and enormous controversy over the efficacy of this procedure. While none of the trials reached the primary endpoint needed to prove the efficacy of PFO closure in preventing recurrent stroke, meta-analyses and 5-year follow-up of 1 trial suggest that PFO closure decreases the risk of recurrent...
Source: European Journal of Internal Medicine - July 3, 2017 Category: Internal Medicine Authors: Jasper R, Blankenship JC Tags: Eur J Intern Med Source Type: research

Safety and efficacy of Cardi-O-fix occluder for percutaneous closure of a patent foramen ovale: A single-center prospective study
Conclusions: There was no significant difference in the short- and mid-term efficacy and safety between the Cardi-O-fix PFO occluder and Amplatzer PFO occluder. The efficacy and safety of the Cardi-O-fix occluder were comparable to those of the Amplatzer PFO occluder.
Source: Medicine - April 1, 2017 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research

AAN recommends against routine closure of patent foramen ovale for secondary stroke prevention
An updated practice advisory from the American Academy of Neurology does not recommend the routine use of catheter-based closure of patent foramen ovale in patients with a history of cryptogenic...
Source: Internal Medicine News - July 27, 2016 Category: Internal Medicine Source Type: research

Patent foramen ovale and cryptogenic stroke: from studies to clinical practice
ConclusionAfter many years of interest on PFO and many concluded studies, there are still no definitive data. However, we are on good track for an appropriate management of PFO patients and cryptogenic stroke.
Source: International Journal of Clinical Practice - July 6, 2016 Category: Internal Medicine Authors: K. Savino, M. Maiello, F. Pelliccia, G. Ambrosio, P. Palmiero Tags: Systematic Review Source Type: research

Patent foramen ovale: Unanswered questions.
Abstract The foramen ovale is a remnant of the fetal circulation that remains patent in 20-25% of the adult population. Although long overlooked as a potential pathway that could produce pathologic conditions, the presence of a patent foramen ovale (PFO) has been associated with a higher than expected frequency in a variety of clinical syndromes including cryptogenic stroke, migraines, sleep apnea, platypnea-orthodeoxia, deep sea diving associated decompression illness, and high altitude pulmonary edema. A unifying hypothesis is that a chemical or particulate matter from the venous circulation crosses the PFO cond...
Source: European Journal of Internal Medicine - October 17, 2015 Category: Internal Medicine Authors: Mojadidi MK, Christia P, Salamon J, Liebelt J, Zaman T, Gevorgyan R, Nezami N, Mojaddedi S, Elgendy IY, Tobis JM, Faillace R Tags: Eur J Intern Med Source Type: research

Successful lysis in a stroke following endovenous laser ablation and extensive miniphlebectomy of varicose veins.
This report describes a successful lysis in a patient with an ischemic stroke associated with bilateral endovenous heat-induced thrombosis class I after endovenous laser ablation of both great saphenous vein and extensive miniphlebectomy in a patient with an unknown patent foramen ovale. PMID: 26447137 [PubMed - as supplied by publisher]
Source: Phlebology - October 6, 2015 Category: Internal Medicine Authors: Spinedi L, Staub D, Uthoff H Tags: Phlebology Source Type: research

Large thrombus entrapped in a patent foramen ovale complicated by stroke and pulmonary embolism.
Authors: Szymańska UA, Rosiak M, Rozbicka J, Kosior DA PMID: 26200927 [PubMed - as supplied by publisher]
Source: Polskie Archiwum Medycyny Wewnetrznej - July 24, 2015 Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research

Current evidence for closure of a patent foramen ovale for cryptogenic stroke prevention
Summary A patent foramen ovale (PFO) has long been implicated as a potential mechanism for cryptogenic stroke (CS), which accounts for up to 40% of all cases of ischaemic stroke. Although there is a strong association between a PFO and CS, there is less evidence that percutaneous closure of the defect, as opposed to medical therapy with antithrombotics or anticoagulants, is the most effective form of secondary prevention. The aim of this review is to examine the evidence comparing percutaneous closure with medical therapy, with a particular focus on three recently published randomised controlled trials.
Source: International Journal of Clinical Practice - December 22, 2013 Category: Internal Medicine Authors: E. Rhone, N. Chung, B. Clapp Tags: Review Article Source Type: research